Intellectual Property Research Associates IPRA, Sep 2010, Pages: 360
of patents and establishing damages for infringement litigation. The seventh edition of RoyaltyRates for Pharmaceuticals & Biotechnology continues to focus on the royaltyrates associated with biotechnology
PharmaVentures, June 2011, Pages: 160
This Report is the pharmaceutical and biotech industry’s standard reference work on royaltyrates.
The 2011 Report presents:
- Major new case studies
- Full, new data and analysis based on data
Frost & Sullivan, Nov 2004
Patent Concerns Restrain Growth in Pharmaceutical and Biopharmaceutical Sectors
Intellectual property rights dilemmas such as patent thickets and royalty stacking are proving to be obstacles
Standard & Poors, Sep 2011
Abstract
Delaware-based Drug Royalty II LP 1 is seeking to issue a US$155 million senior secured term loan due 2016. Standard & Poor's is assigning its 'BB+' long-term corporate credit rating
Standard & Poors, Sep 2011
Abstract
Delaware-based Drug Royalty II LP 1 is seeking to issue a US$155 million senior secured term loan due 2016. Standard & Poor's is assigning its 'BB+' long-term corporate credit rating
Access Asia Ltd., Aug 2006, Pages: 307
.6.2 Sector Breakdown: Sector Shares
Table 1.18 % BREAKDOWN OF OTC PHARMACEUTICALS VALUE SALES BY SECTOR
IN CHINA, 1998-2005
1.6.3 Sector Breakdown: Growth Rates
Table 1.19 % ANNUAL GROWTH FOR VALUE SALES
Pharmalicensing Ltd., Dec 2006, Pages: 144
2006*
Figure 11. Average total upfront payments by stage of development at deal closing ($ million)
Figure 13. Average royaltyrates by stage of development at deal closing (%) - Abbott Pharmaceutical
CurrentPartnering, April 2010, Pages: 510
upfront, milestone and royaltyrates is provided. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you
John Wiley and Sons Ltd, June 2011, Pages: 288
).
APPENDIX H TRADEMARK ROYALTYRATES (NEW).
APPENDIX I PHARMACEUTICAL AND BIOTECHNOLOGY ROYALTYRATES (NEW).
INDEX. Intellectual Property: Valuation, Exploitation and Infringement Damages 2011 Cumulative
Global Markets Direct, Nov 2011, Pages: 205
Million
Vertex Pharmaceuticals Completes Issue Of Convertible Notes For $287 Million
Asset Transactions
Vertex Pharmaceuticals Sells Telaprevir's Future Milestone
Fosamprenavir Royalty Acquires
Global Markets Direct, Nov 2011, Pages: 103
Mar 03, 2005: Cubist Pharmaceuticals to Purchase 2% Reduction in CUBICIN RoyaltyRate from Lilly with Common Stock
Dec 02, 2004: Chiron and Cubist Pharmaceuticals Announce the Filing for EU
Global Industry Analysts, Inc., April 2010, Pages: 258
including many key and niche players such as Aeolus Pharmaceuticals, Inc., Amorfix Life Sciences Ltd., Avicena Group, Inc., Ceregene, Inc., CytRx Corporation, Genzyme Corporation, Isis Pharmaceuticals, Inc
PharmaVentures, Nov 2009
pointers to what is likely to happen in oncology
- An analysis of royaltyrates in oncology
- A comprehensive reference section with case studies of handpicked deals with analysis of SEC contracts
- Deal
Decision Resources, Inc., Dec 2007, Pages: 30
Introduction:
In today’s competitive and evolving pharmaceutical landscape, Business Development is a strategic lifeline for all companies. The more successful Business Development departments
GBI Research, Aug 2010, Pages: 132
Pharmaceuticals in May 2010 121
8.1.3 BioSante Acquires Elestrin Royalty from Azur Pharma in March 2010 121
8.1.4 Teva-KOWA Pharma Acquires Majority Stake in Taisho Pharmaceutical in February 2010 121
8.1.5 Sciele
Business Valuation Resources, July 2010, Pages: 1024
most common types of copyright transfers are assignments and licenses. RoyaltyRates in Copyright Agreements illustrates how others have realized value from their copyrights through licensing
